CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
构建智能 CAR-T 细胞疗法：克服当前挑战的路径
英文原题：Building smart CAR T cell therapies: The path to overcome current challenges.
查看英文原题
Building smart CAR T cell therapies: The path to overcome current challenges.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
成功实施癌症过继细胞治疗（ACT），需要全面应对生物学和实际操作方面的挑战。过去这一综合问题常被忽视，导致ACT的潜在能力与实际疗效之间存在差距。本文总结了构建“理想”ACT产品最有前景的技术策略，重点关注嵌合抗原受体（CAR）工程化细胞。由于有效ACT所需的许多条件为不同癌症所共有，本文提出的策略也可能具有更广泛的适用价值。
展开英文摘要原文
Successful implementation of adoptive cell therapy (ACT) of cancer requires comprehensively addressing biological and practical challenges. This approach has been largely overlooked, resulting in a gap between the potential of ACT and its actual effectiveness.
We summarize the most promising technical strategies in creating an "ideal" ACT product, focusing on chimeric antigen receptor (CAR)-engineered cells. Since many requirements for effective ACT are common to most cancers, what we outline here might have a broader impact.
论文信息
- 作者
- Cai Q、Warren S、Pietrobon V、Maeurer M、Qi LS、Lu TK、Lajoie MJ、Barrett D
- 第一作者单位
- Kite Pharma, 2400 Broadway Boulevard, Santa Monica, CA 90404, USA. Electronic address: qcai@kitepharma.com.United States
- 通讯作者单位
- Sonata Therapeutics, Watertown, MA 02472, USA. Electronic address: fmarincola@sonatatx.com.United States
- 期刊
- Cancer cell2023 Oct 9
- 原文标识
- PubMed 37714150 · DOI 10.1016/j.ccell.2023.08.011